O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
Titel:
O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
Auteur:
Ajani, J. El Hajbi, F. Cunningham, D. Alsina, M. Thuss-Patience, P. Scagliotti, G. Van den Eynde, M. Rybkin, I. Shen, L. Kato, K. Kim, S. D’Alonzo, S. Yu, W. Tao, A. Van Cutsem, E.